Investorideas.com

Call 800 665 0411 to learn about our services

Search   Follow Investorideas on Twitter   Investorideas is on Facebook   Investorideas is on Youtube   Investorideas is on Pinterest  Investorideas is on stocktwits   Investorideas is on tumblr   Investorideas is on LinkedIn   Investorideas Instagram   Investorideas Telegram   Investorideas Gettr   Investorideas RSS


 


BiotechIndustryStocks.com - A Leading Global Investor Website for Biotech Industry Stocks

BiotechIndustryStocks.com - investing ideas in biotechnology stocks, medical technology, telemedicine, Covid-19

Like Biotech Stocks? View our Biotech Stocks Directory    Get News Alerts on Biotech Stocks


Featured Biotech stocks - Feature Your Company & Product Here

Biotech News

Testing Confirms Drug Candidate Differs From Peers
August 11, 2022 (Investorideas.com Newswire) Biotech ProMIS Neurosciences Inc.'s monoclonal antibody in development for Alzheimer's disease boasts a "unique" binding profile that could be "important to its clinical success,"

Biotech Co. Awakes To Good News
August 8, 2022 (Investorideas.com Newswire) Awakn Life Sciences Corp.'s rating went to an Immediate Speculative Buy after it received substantial funding from the UK government.

Biopharma Co. Planning BLA for DMD Drug
August 8, 2022 (Investorideas.com Newswire) Sarepta Therapeutics Inc. recently announced that it intends to submit a BLA to the U.S. FDA for its SRP-9001, a gene therapy to treat Duchenne muscular dystrophy.

MRI Device Maker's Earnings Come In at High End of Forecasts
August 4, 2022 (Investorideas.com Newswire) IRadimed Corp. reported Q2/22 financial results that were modestly higher than expected.

Study Review Shows Greater Promise for Biopharma Co.'s Cough Treatment
August 3, 2022 (Investorideas.com Newswire) After Algernon Pharmaceuticals Inc.'s Ifenprodil treatment for chronic cough was reviewed in a Phase 2 analysis

Expert Says Biotech Co. Is a 'Strong Buy' After Phase 2 Study
August 3, 2022 (Investorideas.com Newswire) Expert Clive Maund gives his assessment of biotech Algernon Pharmaceuticals Inc. after its Phase 2 study of Ifenprodil.

Biotech Co. Granted New Patent for Breast Cancer Vaccine
July 29, 2022 (Investorideas.com Newswire) Last Thursday, Anixa Biosciences Inc. announced that the USPTO granted an extension for the firm's patented breast cancer vaccine technology.

Cancer Co.'s Price Target Adjusted After Reverse Stock Split
July 26, 2022 (Investorideas.com Newswire) Late clinical-stage biopharmaceutical company Cellectar Biosciences Inc. very recently underwent a one for 10 reverse stock split.

Radiotherapy Co. On-Track With Two Clinical Trials
July 26, 2022 (Investorideas.com Newswire) Plus Therapeutics Inc. is developing novel radiotherapy treatments for several rare cancer targets including glioblastoma and leptomeningeal metastases.

Drug Repurposing Co. Provides Opportunity for High Rewards
July 21, 2022 (Investorideas.com Newswire) Vancouver-based pharmaceutical development firm Algernon Pharmaceuticals Inc. recently reported topline data from a Phase 2a trial of ifenprodil in IPF patients with chronic cough

Subscribe to Biotech News RSS

Submit Articles   Search More Articles

Biotech Stock ETF's

First Trust NYSE Arca Biotech ETF ( NYSEArca: FBT ) The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of an equity index called the NYSE Arca Biotechnology Index(SM). The fund will normally invest at least 90% of its net assets plus the amount of any borrowings for investment purposes in common stocks that comprise the index. The index is an equal-dollar weighted index designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services. The fund is non-diversified.

iShares US Healthcare ( NYSEArca: IYH ) The investment seeks to track the investment results of an index composed of U.S. equities in the healthcare sector. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. It seeks to track the investment results of the Dow Jones U.S. Health Care Index (the "underlying index"), which measures the performance of the healthcare sector of the U.S. equity market. The fund is non-diversified.

iShares US Healthcare Providers ( NYSEArca: IHF ) The investment seeks to track the investment results of an index composed of U.S. equities in the healthcare providers sector. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. It seeks to track the investment results of the Dow Jones U.S. Select Health Care Providers Index (the "underlying index"), which measures the performance of the healthcare providers sector of the U.S. equity market. The fund is non-diversified.

iShares US Medical Devices ( NYSEArca: IHI ) The investment seeks to track the investment results of an index composed of U.S. equities in the medical devices sector. The fund seeks to track the investment results of the Dow Jones U.S. Select Medical Equipment Index (the "underlying index"), which measures the performance of the medical equipment sector of the U.S. equity market. The underlying index includes medical equipment companies such as manufacturers and distributors of medical devices such as magnetic resonance imaging (MRI) scanners, prosthetics, pacemakers, X-ray machines, and other non-disposable medical devices. The fund is non-diversified.

iShares Nasdaq Biotechnology ( NasdaqGIDS IBB ) The investment seeks to track the investment results of an index composed of biotechnology and pharmaceutical equities listed on the NASDAQ. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. The underlying index contains securities of NASDAQ® listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals and that also meet other eligibility criteria determined by the NASDAQ OMX Group, Inc. The fund is non-diversified.

Market Vectors Biotech ETF ( NYSE MKT:BBH ) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the Market Vectors® US Listed Biotech 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index is comprised of common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology sector. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.

PowerShares Dynamic Biotech & Genome ETF ( NYSEArca: PBE ) The investment seeks investment results that generally correspond (before fees and expenses) to the price and yield of the Dynamic Biotechnology & Genome IntellidexSM Index. The fund generally will invest at least 90% of its total assets in common stocks of biotechnology companies and genome companies that comprise the underlying intellidex. The underlying intellidex was composed of common stocks of 30 U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified.

Other Ideas - Guest Posts and / or sponsored financial content

Learn how to be published on our site: Buy a guest post on Investorideas.com

Biotech News from Newsfile

Hemostemix Announces Closing of Second Tranche of UNIT Private Placement
Calgary, Alberta--(Newsfile Corp. - August 12, 2022) -  Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) ("Hemostemix" or the "Company") announces that it has closed a second tranche of its previously announced non-brokered private placement of units ("Units") as announced on May 19, 2022 for gross proceeds of $1,364,710.10 (the "Offering"). The Offering consisted of the issuance of an aggregate of 4,549,034 Units at a price of $0.30 per Unit. Each Unit consists of one common share...

Kiora Pharmaceuticals Reports First Half 2022 Business Update and Financial Results
Salt Lake City, Utah--(Newsfile Corp. - August 12, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") today is reporting financial results for the three and six months ended June 30, 2022."In the first half, we continued to advance three core programs toward their next phase of clinical development," said Brian M. Strem, Ph.D., President and Chief Executive Officer of Kiora. "With the recent financing, we are now in a position to continue...

Britannia Mining Solutions Inc. Signs Agreements to Deploy 10 Additional Chrysos PhotonAssay(TM) Units
Britannia Mining Solutions will install and operate a total of 12 Chrysos PhotonAssay™ units in strategically important mining centres globally using an innovative hub-and-spoke modelPositions Britannia as a leader in offering technology-enabled, data rich and ESG friendly assay solutions to the global mining industryFirst PhotonAssay™ unit to be deployed in Q3 2023 in Montreal, serving as an initial regional hub for eastern CanadaToronto, Ontario--(Newsfile Corp. - August 11, 2022) - Britannia Life Sciences Inc. (CSE: BLAB)...

Izotropic Finalizes Engineering and Development Transition to the United States; Establishes Operations in Primary Target Market
Vancouver, British Columbia--(Newsfile Corp. - August 11, 2022) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a MedTech company commercializing IzoView, an advanced three-dimensional computed tomography (3D CT) breast imaging platform for the more accurate detection and diagnosis of breast cancer, is pleased to report the Company has successfully relocated IzoView and associated components and completed the transition of all major medical device engineering and product development operations to...

Optimind Provides Update on Health Canada's Dealer License Under Joint-Venture with Manitari Pharma

Manitari Pharma received approval to begin construction of Security Level 3 safe plus grow rooms, Manitari Pharma is one step closer to obtaining Controlled Substances Dealer's Licence for Psilocybin Research

Toronto, Ontario--(Newsfile Corp. - August 10, 2022) - Optimind Pharma Corp. (CSE:OMND ("Optimind" or the "Company"), an emerging provider of psychedelic therapies, today provides an update on the Company's joint venture with Manitari Pharma Corporation ("Manitari Pharma"), which is 40% owned by Optimind. Manitari Pharma, which has submitted an application to Health Canada for a Controlled Substances Dealer's License for Psilocybin Research Purposes, has begun the process of permitting and planning the build-out of its...

Subscribe to Biotech News